Inex/Hana licensing deal
Executive Summary
Inex signed a Letter of Intent to license three chemotherapy pipeline products to Hana Biosciences, company announces. The oncologics include Marqibo (sphingosomal vincristine), INX-0125 (sphingosomal vinorelbine) and INX-0076 (sphingosomal topotecan). Inex/Enzon's Marqibo was deemed "not approvable" Jan. 14 following an Oncologic Drugs Advisory Committee recommendation against accelerated approval for third-line non-Hodgkin's lymphoma (1"The Pink Sheet" Dec. 6, 2004, p. 20). Under the deal, Hana will develop and commercialize the products and pay Inex $11.5 mil. in upfront payments. Inex also could receive $30.5 mil. in milestone payments...